News for Outlook Therapeutics, Inc. (OTLK)

Overview of the Recent Transaction On January 17, 2025, SPHERA FUNDS MANAGEMENT LTD. (Trades, Portfolio) made a strategic move by acquiring 1,714,284 shares of

ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. ( OTLK), a biopharmaceutical company that achieved regulatory approval in the Europ

**media[553399]**

**media[544681]**

On December 31, 2024, GREAT POINT PARTNERS LLC (Trades, Portfolio) executed a significant transaction by acquiring an additional 926,972 shares of Outlook Thera

Outlook Therapeutics (OTLK) reports Q1 GAAP EPS of $0.72. Key updates include $17.8M warrant proceeds in Jan '25 and $5.7M cash reserves as of Dec '24.

ONS-5010 / LYTENAVAâ„¢ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025LYTENAVAâ„¢ (bevacizumab gamma) o

**media[540806]**

**media[529017,529018]**

**media[522660,522661]**

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into agreements for a warrant inducement transaction.

ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement tra

**media[509538]**

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

Net Loss: Reported a net loss of $75.4 million for fiscal year 2024, compared to a net loss of $59.0 million in the prior year.Earnings Per Share (EPS): EPS of

**media[501427]**

**media[491825]**

First positive reimbursement decision worldwide for LYTENAVAâ„¢; First launch anticipated in H1 2025 LYTENAVAâ„¢ is the first and only approved ophthalmic form

California-based Bolt Projects Holdings, Inc. (BSLK) is up over 233 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.